Login / Signup

Losartan ointment relieves hypertrophic scars and keloid: A pilot study.

Keshvad HedayatyanfardSeyed Ali ZiaiFeizollah NiaziIman HabibiBehnam HabibiHamideh Moravvej
Published in: Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society (2018)
Keloid and hypertrophic scars are two types of fibrosis caused by extracellular matrix overexpression, and angiotensin II via AT1 receptor is known to play a key role in stimulation of fibrosis. A pilot placebo controlled single blind study was carried out on patients with hypertrophic scars and keloids. A total of 37 adult volunteers were randomly assigned into losartan 5% or placebo treatment groups. The treatment was performed twice a day for three months and a 6-month follow-up. The treatment was evaluated using Vancouver scar scale method. Totally, 30 participants were analyzed (Losartan ointment n = 20; placebo ointment n = 10; seven placebo volunteers left the study because they thought the treatment was not effective for them). In the losartan group, VSS scores dropped significantly (p < 0.01) both in keloid and hypertrophic scar patients. Vascularity and pliability were significantly reduced by losartan treatment (p < 0.05). It can be concluded that losartan potassium ointment (5%) can alleviate the keloid and hypertrophic scar.
Keyphrases
  • angiotensin ii
  • squamous cell carcinoma
  • randomized controlled trial
  • placebo controlled
  • cell proliferation
  • young adults
  • open label
  • binding protein
  • phase ii
  • phase ii study